Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509

摘要: Introduction Malignant pleural mesothelioma (MPM) tumors express vascular epithelial growth factor (VEGF) and VEGF receptors. We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy. Methods Patients previously treated platinum-containing chemotherapy regimen performance status 0 to 2 were eligible for enrollment. Cediranib 45 mg/d was administered until progression or unacceptable toxicity. The primary end point response rate. Tumor measurements made by RECIST criteria, subset analysis using modified RECIST. A two-stage design an early stopping rule based on rate used. Results Fifty-four enrolled. Of 47 evaluable patients, 4 (9%) had objective responses, 16 (34%) stable disease, 20 (43%) disease progression, (4%) symptomatic deterioration, 1 patient (2%) death. most common toxicities fatigue (64%), diarrhea hypertension (70%); 91% required dose reduction. Median overall survival 9.5 months, 1-year 36%, median progression-free 2.6 months. Conclusion monotherapy has modest single-agent activity therapy. However, some highly sensitive cediranib. This provides rationale further testing cediranib plus highlights need identify predictive biomarker